Discrimination between patients on adalimumab versus placebo at week 12 using clinical response criteria
| ABILITY-2 | TIPES | |||||||
|---|---|---|---|---|---|---|---|---|
| ADA n (%) N=82 | PBO n (%) N=80 | Pearson's χ2 | p Value | ADA n (%) N=19 | PBO n (%) N=19 | Pearson's χ2 | p Value | |
| PSpARC40 | 33 (41)* | 16 (20) | 8.18 | 0.004 | 7 (37) | 0 (0) | 8.58 | 0.008 |
| PSpARC50 | 29 (36)* | 9 (11) | 13.46 | <0.001 | 6 (32) | 0 (0) | 7.13 | 0.020 |
| PSpARC70 | 19 (24)† | 3 (4) | 13.49 | <0.001 | 3 (16) | 0 (0) | 3.26 | 0.230 |
| ASDAS-MI | 18 (23)† | 5 (6)‡ | 8.04 | 0.005 | 5 (26) | 2 (11) | 1.58 | 0.405 |
| ASDAS-CII | 35 (44)† | 16 (21)‡ | 9.44 | 0.002 | 12 (63) | 4 (21) | 6.91 | 0.020 |
| ASDAS-ID | 27 (34)† | 12 (15)§ | 7.17 | 0.007 | 8 (42) | 0 (0) | 10.13 | 0.003 |
| BASDAI50 | 35 (43) | 15 (19) | 10.90 | 0.001 | 8 (42) | 1 (5) | 7.13 | 0.019 |
| BASDAI≥2 | 39 (48) | 24 (30) | 5.25 | 0.022 | 7 (37) | 2 (11) | 3.64 | 0.124 |
| ACR 20 | 47 (57) | 21 (26) | 16.05 | <0.001 | 9 (47) | 0 (0) | 11.79 | 0.001 |
| ACR 50 | 28 (34) | 8 (10) | 13.66 | <0.001 | 7 (37) | 0 (0) | 8.58 | 0.008 |
| ACR 70 | 15 (18) | 2 (3) | 10.75 | 0.001 | 4 (21) | 0 (0) | 4.47 | 0.105 |
Observed data.
For TIPES, modified PSpARC and ACR were calculated.
*N=81. †N=80. ‡N=77. §N=78.
ACR, American College of Rheumatology; ADA, adalimumab; ASDAS-CII, ASDAS-clinically important improvement; ASDAS-ID, ASDAS-inactive disease; ASDAS-MI, Ankylosing Spondylitis Disease Activity Score-major improvement; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; PBO, placebo; PSpARC, Peripheral SpondyloArthritis Response Criteria; TIPES, Tnf Inhibition in PEripheral SpondyloArthritis.